WST — West Pharmaceutical Services Inc
NYSE · Life Sciences Tools & Services · Life Sciences Tools & Services
- Latest Close
- $309.7
- 30-Day Move
- +16.2%
- Market Cap
- $17.0B
- Shares Outstanding
- 72,080,000
- P/E Ratio
- 36.41
- P/B Ratio
- 6.23
Analyst consensus: Buy · 23 analysts
West Pharmaceutical Services Inc
A read-only Alphactor snapshot forWest Pharmaceutical Services Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$309.7
30-Day Move
+16.2%
Market Cap
$17.0B
Shares Outstanding
72,080,000
P/E Ratio
36.41
P/B Ratio
6.23
$309.70
+16.2%last 90 delayed daily bars
90D High
$320.33
90D Low
$223.83
Avg Volume
937,084
Gross margin is running at 35.9%, which gives a quick read on operating quality before you open the full model.
Net margin is 16.1%, useful for comparing WST against peers in Life Sciences Tools & Services.
WST is up 16.2% over the last 30 trading days shown on this page.
Latest operating income is $175M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$142.88
Rule of 40
21.5%
Dark Pool Short %
63.3%
Latest Close
$309.7
30-Day Move
+16.2%
Market Cap
$17.0B
Shares Outstanding
72,080,000
P/E Ratio
36.41
P/B Ratio
6.23
ROE
15.5%
ROA
11.6%
Gross Margin
35.9%
Operating Margin
19.0%
Net Margin
16.1%
Debt / Equity
0.07
Current Ratio
3.02
Dividend Yield
32.2%
Latest Revenue
$805M
Revenue
$805M
Gross Profit
$304M
Operating Income
$175M
Net Income
$132M
Gross Margin
3591.0%
Net Margin
1606.0%
Current Ratio
3.02
Debt / Equity
0.07
Fair Value
$142.88
Upside / Downside
-53.9%
Signal
Overvalued
Implied Growth
12.4%
DCF
$110.65
EPV
$98.23
EV/Rev
$219.77
Growth Assumption
2.1%
Discount Rate
8.4%
Terminal Growth
2.0%
Base FCF
$469M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
12.33
Safe
Piotroski
7
Strong (7-9)
Cash Conversion
1.53x
Rule of 40
21.5%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $2.9B | $761M | $586M | $439M |
| 2023-12-31 | $2.9B | $707M | $593M | $415M |
| 2024-12-31 | $2.9B | $591M | $493M | $276M |
| 2025-12-31 | $3.1B | $636M | $494M | $469M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | HAUGEN JANET BRUTSCHEA | A | 52 | $250.64 |
| 2026-03-01 | Finch Norman D. Jr. | A | 3,057 | $0.00 |
| 2026-03-01 | Finch Norman D. Jr. | A | 1,285 | $0.00 |
| 2026-03-01 | Green Eric Mark | A | 16,630 | $0.00 |
| 2026-03-01 | Green Eric Mark | A | 6,986 | $0.00 |
| 2026-03-01 | Favorite Annette F | A | 1,712 | $0.00 |
| 2026-03-01 | Favorite Annette F | A | 720 | $0.00 |
| 2026-03-01 | Campbell Shane Alden | A | 2,691 | $0.00 |
Qube Research & Technologies
Filed 2025-11-14
--
--
D.E. Shaw
Filed 2026-02-17
--
--
Two Sigma Advisers
Filed 2025-11-14
--
--
BlackRock
Filed 2024-05-10
$3.0B
--
Vanguard Group
Filed 2026-01-29
$2.6B
-1.7%
Bank of New York Mellon
Filed 2026-02-10
$732M
-8.4%
Geode Capital Management
Filed 2026-02-09
$512M
+0.6%
4.04
Consensus
Buy—
—
—
23
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.